摘要
目的探讨通心络胶囊干预冠心病经皮冠状动脉介入治疗(PCI)术后再狭窄的临床疗效,为冠心病的临床治疗提供有力的依据。方法我院2011年1～12月收治的冠心病患者61例为临床研究对象。两组患者均行经皮腔内冠状动脉成形术。将其随机分为研究组和对照组,研究组患者在常规治疗措施的基础上给予通心络胶囊联合治疗;对照组患者术后仅采用常规治疗。观察并记录两组患者治疗效果,给予统计学分析。结果研究组患者术后即刻靶血管最小直径、狭窄程度以及总复查情况与对照组患者比较差异无统计学意义(P>0.05);研究组患者术后6个月靶血管最小直径、狭窄程度以及再狭窄发生率与对照组患者比较差异具有统计学意义(P<0.05)。结论通心络胶囊能有效降低冠心病患者PCI术后再狭窄发生率,能提高患者治疗效果以及生存质量,具有一定的临床推广价值。
Objective To study the effect of Tongxinluo capsule on restenosis after PCI in patients with CHD. Methods 61 patients with coronary heart disease were recruited in this study,who were performed PCI in our hospital and were divided into the study group and the control group.The study group patients were given Tongxinluo capsule basis on conventional treatment.The control group patients were given conventional treatment.The treatment effects were observed and statistically analyzed. Results The minimum diameter of the target vessel and degree of stenosis were detected after PCI immediately,the results of them as well as reexamination situation had no statistically significant difference in the study group compared with the control group（P 〉 0.05）;6 months post-operative index of the minimum diameter of the target vessel,degree of stenosis and the occurrence of restenosis in the study group had significant differences compared with the control group（P 〈 0.05）. Conclusion Tongxinluo capsule can effectively reduce the occurrence of restenosis after PCI in patients with coronary heart disease,and can improve the quality of life,which is worth spreading in clinical practice.
出处
《中国医药科学》
2013年第12期67-68,共2页
China Medicine And Pharmacy
关键词
通心络胶囊
冠心病
PCI术后再狭窄
Tongxinluo capsule
Coronary heart disease
Restenosis after PCI
